Annovis Bio Inc. announced on June 19, 2025, that it received notification from the New York Stock Exchange (NYSE) confirming the acceptance of its plan to regain compliance with the NYSE's continued listing standards. These standards relate to minimum market capitalization and stockholders' equity. This acceptance provides the company with an 18-month period, starting from the March 26, 2025, notice of noncompliance, to achieve compliance.
During this "Plan Period," Annovis's stock is expected to continue trading on the NYSE, provided the company adheres to its plan and other applicable listing standards. The company is required to provide quarterly updates to the NYSE regarding its progress towards the goals and initiatives outlined in the plan. This acceptance alleviates immediate delisting concerns.
The NYSE's acceptance does not affect the company's business operations or its reporting requirements with the U.S. Securities and Exchange Commission. This development offers a clear pathway for Annovis to address its compliance issues and maintain its listing on the exchange.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.